4.8
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-ac…
When drugs enter the systemic circulation, they interact with blood components like human serum albumin or HSA, α1-acid glycoprotein or AAG, lipoproteins, globulins, and red blood cells or RBCs.
HSA, the most abundant plasma protein, has distinct drug-binding sites. For example, warfarin, certain NSAIDs, and sodium valproate bind to site I. Site II binds benzodiazepines, ibuprofen, and cloxacillin. Few drugs bind to sites III and IV.
AAG binds drugs like imipramine, lidocaine, and propranolol.
Lipophilic drugs, like cyclosporine and amiodarone, bind to lipoproteins, and this binding is influenced by the drug's lipid content.
Steroids like cortisone and prednisone can bind to plasma globulins such as α1-globulin.
Lipophilic drugs exhibit a higher affinity for RBCs than hydrophilic drugs. Specific RBC components, such as hemoglobin, carbonic anhydrase, and cell membranes, can bind distinct drugs.
Drugs like phenytoin bind to hemoglobin, while acetazolamide binds to carbonic anhydrase. Imipramine can bind to the RBC membrane.
View the full transcript and gain access to JoVE Core videos
Q1: What is human serum albumin and why is it important for drug binding?
Human serum albumin (HSA) is the most abundant plasma protein in blood and plays a vital role in drug binding. HSA contains distinct drug-binding sites—sites I, II, III, and IV—each with different drug affinities. For example, warfarin and NSAIDs bind to site I, while benzodiazepines and ibuprofen bind to site II. Understanding HSA binding is essential for predicting drug distribution and pharmacokinetic behavior.
Q2: Which drugs bind to different sites on human serum albumin?
Different drugs exhibit affinity for specific HSA binding sites. Warfarin, certain NSAIDs, and sodium valproate bind to site I. Benzodiazepines, ibuprofen, and cloxacillin bind to site II. Diazepam and insulin detemir bind to site III, while tamoxifen binds to site IV. Only a few drugs bind to sites III and IV compared to the more commonly used sites I and II.
Q3: How do lipophilic drugs interact with blood lipoproteins?
Lipophilic drugs with high lipid content, such as cyclosporine and amiodarone, exhibit strong binding to lipoproteins in the bloodstream. This binding is influenced by the drug's lipid solubility and can significantly impact the drug's distribution and elimination from the body. Understanding lipoprotein binding helps predict how lipophilic drugs move through circulation.
Q4: What role do red blood cells play in drug binding?
Red blood cells (RBCs) bind drugs through specific components including hemoglobin, carbonic anhydrase, and cell membranes. Lipophilic drugs show higher affinity for RBCs than hydrophilic drugs. For example, phenytoin binds to hemoglobin, acetazolamide binds to carbonic anhydrase, and imipramine binds to the RBC membrane. This binding affects factors affecting protein drug binding patient related factors and overall drug distribution.
Q5: How does alpha-1-acid glycoprotein differ from human serum albumin in drug binding?
Alpha-1-acid glycoprotein (AAG) is another plasma protein that binds drugs like imipramine, lidocaine, and propranolol. Unlike HSA, which has multiple defined binding sites, AAG binds a more specific set of drugs and influences their distribution and pharmacokinetics. AAG levels can vary among patients, affecting individual drug responses and therapeutic outcomes.
Q6: Which steroids bind to plasma globulins and what is the significance?
Steroids like cortisone and prednisone bind to plasma globulins, particularly alpha-1-globulin. This binding influences the distribution and pharmacological effects of these drugs throughout the body. The extent of globulin binding affects how much free, active drug is available for therapeutic action, making it important for understanding steroid pharmacokinetics.
Q7: Why is understanding drug-blood component interactions important in pharmacology?
Understanding how drugs interact with blood components—HSA, AAG, lipoproteins, globulins, and RBCs—is vital for predicting drug distribution, metabolism, and pharmacokinetic behavior. This knowledge helps optimize drug therapy, identify potential drug-drug interactions, and ensure effective and safe pharmacological outcomes for patients receiving medications.